Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …
…, SM Murillo, IA Mayer, JA Means-Powell… - The lancet …, 2017 - thelancet.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation
…, IA Mayer, IM Meszoely, JA Means-Powell… - Clinical Cancer …, 2010 - AACR
Purpose: To identify molecular markers of pathologic response to neoadjuvant paclitaxel/radiation
treatment, protein and gene expression profiling were done on pretreatment biopsies. …
treatment, protein and gene expression profiling were done on pretreatment biopsies. …
A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer
…, IM Meszoely, JA Means-Powell… - Physics in Medicine …, 2011 - iopscience.iop.org
Quantitative analysis of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
data requires the accurate determination of the arterial input function (AIF). A novel method …
data requires the accurate determination of the arterial input function (AIF). A novel method …
[HTML][HTML] Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
…, L Goff, GK Dy, P Zucali, JA Means-Powell… - Investigational New …, 2015 - Springer
Purpose This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD),
and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients …
and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients …
[HTML][HTML] A phase Ib dose escalation trial of RO4929097 (a γ-secretase inhibitor) in combination with exemestane in patients with ER+ metastatic breast cancer (MBC)
JA Means-Powell, IA Mayer, R Ismail-Khan… - Clinical breast …, 2022 - Elsevier
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen
signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational …
signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational …
Motion correction in diffusion‐weighted MRI of the breast at 3T
…, MC Kelley, IA Mayer, JA Means‐Powell… - Journal of Magnetic …, 2011 - Wiley Online Library
Purpose: To provide a quantitative assessment of motion and distortion correction of
diffusion‐weighted images (DWIs) of the breast and to evaluate the effects of registration on the …
diffusion‐weighted images (DWIs) of the breast and to evaluate the effects of registration on the …
Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer
…, MC Kelley, IM Meszoely, J Means-Powell… - Investigative …, 2015 - journals.lww.com
Objectives The purpose of this study was to determine whether multiparametric magnetic
resonance imaging (MRI) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-…
resonance imaging (MRI) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-…
DCE‐MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings
…, IM Meszoely, J Means‐Powell… - Magnetic resonance …, 2014 - Wiley Online Library
Purpose The purpose of this pilot study is to determine (1) if early changes in both semiquantitative
and quantitative DCE‐MRI parameters, observed after the first cycle of neoadjuvant …
and quantitative DCE‐MRI parameters, observed after the first cycle of neoadjuvant …
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next …
…, J Knol, J Gilbert, I Puzanov, J Means-Powell… - The …, 2014 - academic.oup.com
Background. Oncogenic genetic alterations “drive” neoplastic cell proliferation. Small molecule
inhibitors and antibodies are being developed that target an increasing number of these …
inhibitors and antibodies are being developed that target an increasing number of these …
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
…, LW Goff, GJ Fetterly, SA Michael, JA Means-Powell… - 2012 - ascopubs.org
4117 Background: The multikinase inhibitor sorafenib is standard of care for pts with advanced
HCC. Tivantinib, an oral, selective MET inhibitor, demonstrated synergistic antitumor …
HCC. Tivantinib, an oral, selective MET inhibitor, demonstrated synergistic antitumor …